It is now possible to manipulate the mammalian germline to generate transgenic mice that either overexpress a wild-type or mutant gene or lack a functional copy of an endogenous gene. In particular, the rapid advances in embryonic stem (ES) cell technology for generating mice functionally deficient in specific gene products (that is, knockout mice) have allowed investigators to address the unique and essential functions of these gene products in vivo. These studies have advanced research on mammalian reproduction, since the hypothalamic-pituitarygonadal axis is a complex network that requires in vivo analysis to define function. Several genes essential for sex determination and establishment, and maintenance of the reproductive system have been addressed using transgenic mouse technology. This has given many valuable clues to understanding the function of those genes in vivo. For studying the establishment of the mammalian reproductive system, it is necessary to understand the following four sequential processes (Bogan and Page, 1994; Camper et al.; Marx, 1995) :
(1) Induction of mesoderm in the embryo and development of the urogenital rudiment from mesonephros, a sex chromosome independent event.
(2) Development of a testis or ovary from a urogenital ridge which is initially determined by the sex chromosome status of the embryo.
(3) Subsequent development or regression of the 'conduit' ducts derived from the Wolffian duct (male) and Müllerian duct (female), testis-influenced processes.
(4) Maintenance and regulation of gametogenesis, steroidogenesis, growth, and differentiation in the fetal, postnatal, and adult ovaries and testes.
At each step, several genes including transcription factors, growth factors and receptors are activated to continue the maintenance of the species. In this review, we summarize results obtained mainly by the application of transgenic techniques in reproductive research to reveal or confirm the functions of multiple genes in sex determination, subsequent establishment of several reproductive tissues, and the maintenance of gametogenesis and the reproductive cycle.
Genetic manipulation of the mouse germline
The last 15 years have seen rapid changes and increases in the use of transgenic mouse technology for studying mammalian development (for review, see Palmiter and Brinster, 1986; Hanahan, 1989; Bradley et al., 1992; Capecchi, 1994; Camper, et al., 1995; Matzuk, 1995) . The earliest studies used microinjection of DNA (transgenes) into the male pronucleus of fertilized mouse eggs. These injected eggs are then transferred back to the oviducts of pseudopregnant female hosts for continued development. In these cases, mice that have incorporated one, or frequently many, copies of the transgene into their genome are referred to as transgenic mice. The majority of these experiments have resulted in 'gain of function' transgenic mice, since there is inappropriate expression of a gene product that normally is not expressed in mice. Occasionally, when these transgenic hemizygous mice are bred to homozygosity, a recessive effect is uncovered caused by an insertional mutation of the transgene. In addition, tissue/cell-specific expression of cell lethal genes, such as diphtheria toxin, or marker genes, such as β-galactosidase, has made it possible to study cell lineage development.
More recently, the use of embryonic stem (ES) cell technology has permitted a much broader application of the above transgenic techniques. Embryonic stem cells are pluripotential cells that were initially isolated from the inner cell mass (embryonic portion) of mouse blastocysts. Embryonic stem cell lines have been developed that can be maintained in culture in a pluripotential state. DNA can be introduced into these ES Transgenic mice have become important model systems for studying molecular, cellular, organ, and whole animal physiology. In particular, transgenic technology allows determination of cell lineage differentiation and the role(s) of specific proteins in mammalian development and oncogenesis. Transgenic mice can be created that express wild-type genes, mutant genes, marker genes or cell lethal genes in a tissue-specific manner. In addition, homologous recombination strategies in embryonic stem cells permit more sophisticated manipulation of the mammalian genome, including the functional deletion of specific genes in whole mice or in a specific tissue. Since all transgenic mice created must be bred to study the consequences of transgene or mutant allele expression, a number of effects of these genome manipulations on the reproductive development and function of these mice have been uncovered. In this review, we summarize the transgenic mouse models in which defects and abnormalities in the reproductive axis have been demonstrated. cells and, depending on the transgene or targeting vector that is introduced, ES cells with the correctly manipulated DNA can be scored. These manipulated ES cells can be introduced into blastocysts and can contribute to the germline of the chimaeras: the transgenic mice generated can then be followed for the presence of the manipulated DNA. For example, if the introduced DNA vector is homologous to an endogenous mouse DNA segment and the vector has been engineered to contain a deletion or mutation of the mouse DNA sequence, homologous recombination between this introduced DNA vector and the endogenous DNA will result in an alteration of the endogenous sequences. By this strategy, precise mutations or deletions of the mouse genome can be generated and, in the process, functional alteration of any mouse DNA sequences or genes is now possible. Thus, ES cell technology enables one to generate 'loss of function' transgenic mice to address the essential and relevant roles of a gene product in mammalian development in vivo. In particular, our research has been focused on using both pronuclear microinjection and ES cell strategies to study reproductive development and function. Tables 1 to 5 outline the various transgenic and mutant mice that have been created or discovered in which there are effects on the reproductive axis. In this short review, we will focus only on a few of these mouse models; readers who wish more information are directed to the original manuscripts.
Sex determination and early reproductive development
Experiments over 40 years ago by Alfred Jost (Jost, 1953) suggested that there were two substances synthesized by the testis that were necessary for sexual development. In the absence of the testes, a female ductal system formed (the 'default' pathway). Jost's early experiments, as well as later studies with transgenic mice (Table 1), confirmed that the two major substances were androgens and Müllerian inhibiting substance (MIS). The tfm (testicular feminization) mouse has a mutation in the androgen receptor gene (Charest et al., 1991; He et al., 1991) on the X chromosome leading to female internal and external genitalia. The Wolffian duct, which normally forms the epididymis, vas deferens and seminal vesicles, requires testosterone action. Development of male external genitalia and prostate requires the conversion of testosterone to dihydrotestosterone by the enzyme steroid 5α-reductase. Mice that are X tfm Y have testes but lack Wolffian ducts and have female external genitalia because of the absence of androgen action. Müllerian ducts (the precursors of the oviducts, uterus and upper vagina) do not develop because the testes continue to produce MIS.
Confirmation of the second of Jost's substances came in the 1990s. Transgenic mouse experiments (Behringer et al., 1990 (Behringer et al., , 1994 showed that overexpression of MIS in female mice caused regression of the Müllerian duct, and absence of MIS in male mice prevented this regression and led to males with both Wolffian and Müllerian duct derivatives (Tables 1, 3 ). The MIS receptor is not expressed in the Müllerian duct but in the adjacent mesenchyme (Baarends et al., 1994) , suggesting that other intermediate factors are required for Müllerian duct regression.
Although Jost had postulated that only two factors are required for sexual differentiation and development, it is obvious that many upstream and downstream gene products are also required for these processes (Table 1 ; Bogan and Page, 1994; Marx, 1995) . Early experiments had suggested that the presence of the Y chromosome (no matter how many X chromosomes) was male determining, whereas the absence of the Y chromosome resulted in a female genotype (McLaren, 1990; Bogan and Page, 1994) . However, it took over three decades of exhaustive research using both sex reversed humans and mice before the sex-determining region Y genes (SRY, human; Sry, mouse) were identified as the putative testis determining genes (see Bogan and Page, 1994) . Sry/SRY is a transcription factor with a DNA-binding motif homologous to the high-mobility-group proteins HMG1 and HMG2. Consistent with its important role in testis determination, Sry is expressed in the genital ridge of the male mouse during the 36 h immediately preceding overt testis differentiation (at an embryonic age of about 12.5 days). However, definitive proof that Sry determines gonadal differentiation came from transgenic mouse experiments in which a 14 kb DNA fragment of the Y chromosome including the Sry gene caused XX mice to develop testes and appear phenotypically male (Koopman et al., 1991) . The absence of spermatozoa in these sex-reversed transgenic mice, similar to most sex-reversed male humans and mice, confirmed that other Y chromosome genes are necessary for normal male reproductive function. More recently, transgenic mouse technology and human disease studies have identified several other genes that function either upstream or downstream of Sry (Table 1 ). In particular, WT-1 and SF-1 are expressed in the urogenital ridge beginning at an embryonic age of about 9 days. Mice lacking either the transcription factor WT-1 (Wilms' tumour associated gene; Kriedberg et al., 1993) or the orphan nuclear hormone receptor SF-1 (steroidogenic factor 1; Luo et al., 1994) demonstrate failure of the urogenital ridge to develop beyond the earliest stages of gonadal development, leading to complete gonadal agenesis. It is unclear, however, whether WT-1 and SF-1 are acting in the same pathway to regulate development of the indifferent gonads. In the case of SF-1, several other important downstream genes have been identified, including MIS (Shen et al., 1994) and the orphan nuclear hormone receptor, DAX-1 (Burris et al., 1995) . Mutations in DAX-1 are associated with X-linked hypoplasia congenita and hypogonadotrophic hypogonadism (Muscatelli et al., 1994; Zanaria et al., 1994) . The similar expression patterns of SF-1 and DAX-1 suggest that SF-1 may regulate/modulate DAX-1 expression and function.
Lastly, mutations in the human SRY-related gene, SOX-9, result in campomelic dysplasia and XY females, suggesting that it is an important downstream gene of SRY (Foster et al., 1994; Wagner et al., 1994) .
Extragonadal regulation of reproductive function
The gonadotrophic hormones, luteinizing hormone (LH) and follicle stimulating hormone (FSH), are members of the glycoprotein hormone superfamily, which also includes thyroid stimulating hormone (TSH) and human chorionic gonadotrophin (hCG). These hormones share common α subunits but have unique β subunits. Both LH and FSH, synthesized in the gonadotrophs of the anterior pituitary, are believed to play key roles in gonadal growth, differentiation, gametogenesis and steroidogenesis. Confirmation of the dual roles of these hormones in vivo has been enlightened by several transgenic and mutant mouse models.
The hypothalamic peptide, gonadotrophin releasing hormone (GnRH), is a major regulator of LH and FSH synthesis and secretion. In contrast, inhibins and activins, members of the transforming growth factor β (TGF-β) superfamily, which are synthesized both in the pituitary and gonads, exclusively regulate FSH. Two mouse models, the hypogonadal (hpg) mouse and a human GnRH promoter-SV40 T antigen transgenic mouse, have small testes and ovaries and complete infertility owing to suppressed or absent GnRH synthesis (Table 4) . hpg/hpg mice are hypogonadal due to a null mutation (deletion) in the GnRH gene (Mason et al., 1986) leading to suppressed LH and FSH concentrations (Cattanach et al., 1977) . Aberrant expression of the SV40 tumour antigen in GnRH-SV40 T antigen transgenics (Radovick et al., 1991) arrests the migration of the GnRH neurones, results in T antigen/GnRH positive tumours along the normal migrating path of these neurones, and leads to infertility. Thus, these two models are excellent in vivo systems for understanding hypogonadotrophic hypogonadism secondary to GnRH absence. Several other mouse models and strategies have been developed to study pituitary LH and FSH actions directly. Two different mouse models have been generated in which a cell lethal gene product has been directed to the gonadotrophs of the pituitary. In the first study, the bovine glycoprotein hormone α subunit promoter was used to direct diphtheria toxin A chain (DT) expression to the gonadotrophs (Kendall, et al., 1991) . The diphtheria toxin expression led to ablation of the gonadotrophs, and the transgenic mice that resulted had a phenotype that mimicked the hpg model described above (the mice were hypogonadal due to absence of LH and FSH resulting in infertility). Thus, these studies suggested that the phenotypic effects in the hpg mice were due to absence of LH and FSH and not due to loss of GnRH activity.
In contrast to the bovine α promoter-DT transgenic mice, mice that have directed expression of the herpes simplex virus thymidine kinase (HSV-tk) to gonadotrophs and have been treated with a cell lethal nucleoside analogue fail to show a marked effect on either LH or FSH expression or on reproductive function (Camper et al., 1995; Markkula et al., 1995) . This minimal effect may be due to the post-mitotic state of the gonadotrophs when the HSV-tk expression is utilized (that is, the nucleoside analogues were supplied post-natally). Use of HSV-tk also has other problems owing to its expression from cryptic promoters in the testis leading to sperm defects and infertility (Table 3) , even in the absence of nucleoside analogue treatment (Braun et al., 1990; Huttner et al., 1993) .
Four different transgenic knockout models using ES cell technology have also been developed in which the pituitary gonadotroph expression of the gonadotrophins is effected. Absence of the glycoprotein hormone α subunit leads to a reproductive phenotype similar to the above hpg model (Kendall et al., 1995) . However, besides being hypogonadal and infertile, the mice are also small and hypothyroid owing to the additional absence of TSH (TSH also shares a common α subunit with LH and FSH). Thus, this model has a broader phenotype than the hpg model due to the absence of the α subunit in both gonadotrophs and thyrotrophs.
Three other models have been developed by our laboratory in which the regulation of FSH expression by inhibins and activins has been evaluated. Inhibins cause a decrease in FSH synthesis and secretion, whereas activins increase FSH synthesis and secretion. Mice lacking the inhibin α subunit (Table 4) demonstrate increased FSH concentrations, confirming the known function of inhibins (Matzuk et al., 1992) . Mice deficient in the inhibin/activin βB subunit (Table 2 ) have raised concentrations intermediate between wild-type and inhibin-deficient mice (Vassalli et al., 1994) . In this case, absence of inhibin B appears to have a greater effect than absence of activin B (the inhibin/activin βB subunit is shared between these two growth factors). In contrast, mice deficient in activin receptor type II have markedly suppressed pituitary and serum concentrations of FSH (Matzuk et al., 1995b) . Thus, this receptor appears to be the major pituitary receptor through which activins regulate FSH synthesis and secretion. In addition, the suppressed FSH synthesis in the activin receptor type II-deficient mice leads to a hypogonadal phenotype in both sexes, delayed fertility in males, and infertility in females (Table 4 ).
Transgenic models to study intragonadal function
In addition to the development of gonadal tumours in transgenic mice, which is discussed in the next section, several groups have generated transgenic mouse models in which gonadal function is altered directly. There have been several examples in which transgene insertion mutations have disrupted spermatogenesis in the male (Table 3) . In this section, we will focus on transgenic mice with altered expression of c-mos, the oestrogen receptor and the progesterone receptor.
In one study, c-mos was overexpressed in the testes of transgenic mice using the pre-meiotic male germ cell specific promoter: the mouse phosphoglycerate kinase 2 (PGK) gene promoter (Table 5 ; Higgy et al., 1995) . C-mos protein expression was shown to be raised in spermatids and spermatocytes in this transgenic line and resulted in a significant increase in the number of germ cells; however, no aberrant fertility differences were apparent in these transgenic male mice. Similarly, absence of c-mos in knockout experiments did not alter the fertility of male mice (Colledge et al., 1994; Hashimoto et al., 1994) , suggesting that c-mos is not essential for male germ cell development and function. However, female mice lacking c-mos demonstrated greatly reduced fertility (Table 2 ). There were fewer pregnancies and a decrease in the litter size in mice that produced litters, and many of the c-mos-deficient females were completely infertile. The fertility defect was due to failure of the c-mos-lacking oocytes to arrest during meiosis. Oocytes matured to the second meiotic metaphase and were activated without fertilization, demonstrating that c-mos plays a key role in the second meiotic metaphase arrest. In addition, over 25% of the mice over 4-6 months of age developed teratomas/ovarian cysts which also caused secondary infertility. Similar to the c-mos knockout mice, male mice lacking the progesterone receptor are fertile but females have fertility defects (Table 2 ; Lydon et al., 1995) . Absence of progesterone receptors in females leads to a failure of oocytes to be released from Graafian follicles resulting in complete infertility. In addition, progesterone receptor-deficient female mice have morphological and histological defects in the uterus and mammary gland, and absence of behaviour responses (progesterone stimulated lordosis) suggests that there is a brain defect. These studies demonstrate that progesterone plays a pleiotropic role in a number of diverse reproductive processes.
Transgenic mice overexpressing or lacking oestrogen receptors have been created. A metallothionein-I (MT) promotermouse oestrogen receptor cDNA transgene resulted in oestrogen receptor transgene expression in a number of tissues including the uterus (highest expression) and ovary (Table 2 ; Davis et al., 1994) . These MT-oestrogen receptor transgenic female mice displayed reduced fertility secondary to prolonged gestation (up to 4 days longer) and prolonged labour (up to 3 days longer). As the adult female mice aged, 100% of these transgenic mice displayed dystocia, stillborn litters and prolonged labour. The majority of these defects were probably due to aberrant spatiotemporal expression of oestrogen receptors in the uterus.
In contrast to the MT-oestrogen receptor transgenics, both male and female mice lacking oestrogen receptors are infertile (Table 4 ; Lubahn et al., 1993; Korach, 1994) . The male oestrogen receptor-deficient mice have small testes, fewer spermatozoa (<10% of control) in the epididymis, and fewer germ cells and spermatozoa in many of the seminiferous tubules that appear dysmorphogenic. Infertility in oestrogen receptor-deficient female mice is due to uterine, ovarian and CNS defects. The uteri are hypoplastic and unresponsive to oestradiol, the ovaries display cysts and haemorrhagic follicles, and the mice fail to demonstrate any lordosis posture, similar to the progesterone receptor knockouts, suggesting a CNS defect. Thus, oestrogen receptor-deficient female mice are infertile as expected. The infertility in the oestrogen receptor-deficient males is surprising and suggests an important role for oestrogens in male testis function.
Tumour formation in the hypothalamic-pituitary-gonadal axis
Several transgenic mouse models have been created in which tumours develop in the hypothalamic-pituitary-gonadal axis. et al. (1995) bcl-2 knockout Histologically abnormal primordial follicles Ratts et al. (1995) Prostaglandin synthase 1 knockout Decreased live offspring from homozygous cross homozygous matings Langenbach et al. (1995) Human FSHβ gene transgenic Increased chimaeric mouse/human FSH but no reproductive defects Kumar et al. (1992) Bovine oxytocin gene transgenic Normal fertility but decreased testicular androgens Ang et al. (1994) MT-transforming growth factor α Modulatory role of TGFα in the hypothalamus and ovary Ma et al. (1994) Bovine FSHβ promoter-HSV-tk Normal fertility despite decreased FSH/LH Markkula et al. (1995) Bovine glycoprotein α promoter-HSV-tk Normal fertility, although some males showed decreased testis size Camper et al. (1995) PGK-cmos Normal fertility; increased germ cell number Higgy et al. (1995) Rat probasin promoter-SV40 T antigen Prostate neoplasia Greenberg et al. (1995) Human glycoprotein hormone α subunit Pituitary gonadotroph (α subunit secreting) tumours Windle et al. (1990) Inhibin α promoter-SV40 T-Ag Granulosa cell tumours; Leydig cell tumours Kananen et al. (1995) Similar to the case in humans, the development of these tumours usually results in secondary infertility. As mentioned above, human GnRH promoter-SV40 T antigen transgenic mice develop tumours in the hypothalamus along the normal course of migration of the GnRH neurones (Table 4 ; Radovick et al., 1991) . In a similar way, directed expression of SV40 T antigen using the glycoprotein hormone α subunit promoter (Windle et al., 1990) , the rat probasin promoter (Greenberg et al., 1995) , the MIS promoter (Peschon et al., 1992) , and the inhibin α promoter (Kananen et al., 1995) leads to pituitary gonadotroph tumours, prostate tumours, Sertoli cell tumours, and granulosa and Leydig cell tumours, respectively (Table 5 ). In several other transgenic models, inadvertent expression of oncogenes in the testes has resulted in germ cell tumours (Kondoh et al., 1991) , Leydig cell tumours (Chalifour et al., 1992) , and Sertoli cell tumours (Paquis-Flucklinger et al., 1993) (Table 5) . Lastly, overexpression of an LH subunit analogue, the LHβ subunit with the hCGβ carboxyl-terminal peptide (CTP) extension under the control of the bovine α subunit promoter (that is, gonadotroph directed expression), has led to the development of infertility, polycystic ovaries, and eventually granulosa cell tumours (Risma et al., 1995) . The presence of the hCGβ CTP increased the serum half-life of the chimaeric mouse α: bovine LHβ-CTP and led to the tumour development.
In four different knockout mouse models, tumours in the testes and ovaries are also seen. As described in the previous section, female mice lacking c-mos develop teratomas (Colledge et al., 1994; Hashimoto et al., 1994) (Table 2) . As well as many other tumour types, male mice homozygous for a mutation in p53, the tumour suppressor gene, develop teratocarcinomas at a low incidence (Table 5) . When the genetic background of the mouse on which the mutation was present was hybrid (that is, C57BL/6/129SvEv mixed background), four out of 44 (9%) males developed teratocarcinomas (Donehower et al., 1992; Harvey et al., 1993) . When the p53 null mutation was present on a 129SvEv inbred mouse background, approximately 44% of the p53-deficient homozygote mutant male mice (eight out of 18 mice) developed testicular teratocarcinomas.
Inhibins were initially discovered for their role in regulating pituitary FSH production. However, other intragonadal roles of inhibins have also been postulated. We have confirmed the roles of inhibins in downregulating FSH synthesis and have also proven that inhibins play an important anti-proliferative role in the gonads. We have shown that essentially 100% of mice deficient in the α inhibin subunit develop granulosa/ Sertoli cell tumours of the ovaries and testes (Matzuk et al., 1992;  Table 4 ). These tumours develop at an early age (as early as 4 weeks of age) and have been seen as focal lesions. The tumours grow rapidly and always cause lethality due to a secondary cancer cachexia-like syndrome (Matzuk et al., 1994) . The cancer cachexia-like syndrome is mediated by an increase in the secretion of activins from the tumours (Matzuk et al., 1994) which signal through activin receptor type II in the glandular stomach and liver (Coerver et al., 1996) . The predisposition of inhibin-deficient mice to tumours has identified inhibin as a novel tumour suppressor, the first secreted protein that has this function. The complete penetrance of tumours in the inhibin-deficient mice is allowing us to identify other modifier factors that are required for ovarian and testicular tumour development.
In addition to the Müllerian duct defects, MIS-deficient male mice also develop testicular Leydig cell hyperplasia and in one case a Leydig cell tumour (Behringer et al., 1994) (Table 3) . Müllerian inhibiting substance has also been shown to inhibit the proliferation of some cancer cell lines. To evaluate further the roles that MIS and inhibin play as anti-proliferative growth factors within the testes and ovaries, we generated mice deficient for both inhibins and MIS via a genetic intercross (Matzuk et al., 1995a) . Female mice deficient in both inhibin and MIS were identical to mice deficient in inhibin alone. However, inhibin/MIS-deficient males developed granulosa/ Sertoli cell tumours at an earlier age and also developed Leydig cell neoplasia (Table 3 ). Focal Leydig cell neoplastic lesions were seen as early as 7 days of age. These results suggest that inhibins and MIS synergize to influence testicular tumour development and also suggest that these TGF-β superfamily members share a common signalling pathway in the Sertoli and Leydig cells of the testes. Furthermore, the inhibin/ MIS-deficient male mice develop large fluid-filled uteri, in part due to oestradiol secretion from the testicular tumours.
Transgenic mice with defects outside the hypothalamic-pituitary-gonadal axis
In addition to the above transgenic models with defects in the hypothalamic-pituitary-gonadal axis, there are also several transgenic models that have abnormalities outside this axis. The homeobox Hoxa10 knockout, Hoxa-11/Hoxd-11 double knockouts, leukaemia inhibitory factor (LIF) knockout, activin/ inhibin βB knockout, and α-lactalbumin knockouts are among the transgenic mice with the most interesting phenotypes (Tables 2, 4 , 5). The majority of transgenic mice lacking homeobox genes have resulted in mice with skeletal defects, including homeotic transformations. Mice that lack both Hoxa-11 and Hoxd-11 (Davis et al., 1995) have an interesting urogenital defect: the vas deferens of the double mutants is much smaller in diameter, more coiled and appears more epididymis-like compared with that of wild-type mice. These findings suggest that a homeotic transformation has occurred in these Wolffian duct derivatives in the absence of these two homeobox paralogues. Both male and female mice deficient in Hoxa-10 have infertility defects (Satokata et al., 1995) . Hoxa-10 knockout males have bilateral cryptorchidism with failure of the testes to enter the scrotum. This cryptorchidism (due to a disorganized and reduced number of cremasteric muscle myocytes) resulted in small testes, atrophic seminiferous tubules, and a 40% rate of sterility in 6-12 week old mice. An increase in the number of infertile males was noted with age. In contrast, although absence of MIS has also been suggested to play a role in cryptorchidism, the testes of MIS-deficient mice are present in the scrotum (Behringer et al., 1994) . Similarly, a large number of Hoxa-10 deficient females (78%) are also infertile owing to death of embryos between the embryonic ages of 2.5 and 3.5 days. This embryonic death occurs at the time when Hoxa-10 is expressed in the maternal distal oviduct and uterus, suggesting that Hoxa-10 regulates a factor required for preimplantation embryo viability. In a similar way, although LIF-deficient female mice can ovulate normally, blastocysts are incapable of implanting into the uterus which normally expresses LIF (Stewart et al., 1992) . Thus, these LIF-deficient females are infertile owing to a maternal uterine defect and demonstrate that LIF expression in the maternal uterus is required for extragonadal reproductive function.
Lastly, two knockout models demonstrate reduced ability for offspring to survive post-natally due to maternal nursing defects (Table 2 ). Male and female mice deficient in α-lactalbumin, an abundant milk-specific metalloprotein, are viable and fertile (Stinnarke et al., 1994) . However, offspring born to α-lactalbumindeficient females die owing to their inability to remove milk from their mothers (suckling is normal). In the absence of α-lactalbumin, the milk in the mammary glands of these transgenic mice is viscous and also deficient in lactose, making it impossible for the offspring to obtain any milk. In a similar way, the majority of mice deficient in the activin/inhibin βB subunit fail to nurse their offspring (Vassalli et al., 1994) . Despite normal accumulation of milk in the lobules and ducts of these activin/inhibin βB-deficient mothers, most of their offspring die perinatally apparently owing to impairment of milk let-down. In addition, parturition is delayed by 1-2 days in the majority of the mutant females. It is unclear whether the deficiency in activin B in the breast, uterus or hypothalamus is directly or indirectly affecting labour and nursing.
Conclusions
Over 50 different transgenic mouse mutants have been generated in which there are effects in the reproductive axis. We have described mice that have infertility defects owing to effects at all levels of the hypothalamic-pituitary-gonadal axis. Tumour development in this axis can also lead to primary or secondary infertility. In addition, several of these mouse mutants have defined factors required for sex determination and early reproductive development. These transgenic mice will continue to yield important information for defining reproductive development and function.
